Urolithin A attenuates diabetic kidney disease by inhibiting ferroptosis via activation of the Nrf2/HO-1 signaling pathway

Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, plays a critical role in renal tubular injury in diabetic kidney disease (DKD). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a central regulator of cellular redox homeostasis and lipid peroxidation, thereby exerting a pivotal influence on ferroptosis. Urolithin A (UA), a gut microbiota-derived metabolite, exhibits potent antioxidant and anti-glycation properties and has demonstrated protective effects in diabetic models. This study aimed to investigate the renoprotective effects of UA in DKD and to determine whether these effects are mediated through inhibition of ferroptosis via activation of the Nrf2/HO-1 signaling pathway. A DKD model was established using db/db mice, which were randomly assigned to four groups: db/m , db/m + UA, db/db , and db/db + UA. After 10 weeks of UA administration by gavage, renal function, histopathological changes, and markers of oxidative stress and ferroptosis were evaluated. In vitro, HK-2 cells were exposed to high glucose to mimic the diabetic milieu, followed by UA treatment to assess cellular injury and associated molecular alterations. The involvement of the Nrf2 pathway was further validated by siRNA-mediated knockdown of Nrf2. UA significantly improved renal function in db/db mice, as indicated by decreased blood urea nitrogen and urinary albumin-to-creatinine ratio (UACR), along with marked attenuation of renal histopathological damage. UA effectively suppressed oxidative stress both in vivo and in vitro, as evidenced by reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), and increased glutathione (GSH) content. Furthermore, UA modulated ferroptosis-related proteins by downregulating ACSL4 and upregulating GPX4 and SLC7A11. These effects were accompanied by enhanced nuclear translocation of Nrf2 and increased expression of HO-1. Notably, Nrf2 knockdown largely abrogated the protective effects of UA. UA attenuates the progression of DKD by activating the Nrf2/HO-1 signaling pathway, thereby inhibiting oxidative stress and ferroptosis. These findings suggest that UA may serve as a promising therapeutic candidate for the treatment of DKD.

Authors

Institutions

Publication Details

Journal
Cell Biology and Toxicology
Published
2026-11-18
DOI
https://doi.org/10.1007/s10565-026-10342-5
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urolithin A attenuates diabetic kidney disease by inhibiting ferroptosis via activation of the Nrf2/HO-1 signaling pathway

Xiping Fang, Weiquan Xie, Weiwei Li, Changyu Zhou et al.
7 links
Cell Biology and Toxicology
Ferroptosis and cancer prognosis
article

Urolithin A attenuates diabetic kidney disease by inhibiting ferroptosis via activation of the Nrf2/HO-1 signaling pathway

Xiping Fang, Weiquan Xie, Weiwei Li, Changyu Zhou, Zhuan Peng, Bo Qin, Guogen Sun
article en

Abstract

Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, plays a critical role in renal tubular injury in diabetic kidney disease (DKD). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a central regulator of cellular redox homeostasis and lipid peroxidation, thereby exerting a pivotal influence on ferroptosis. Urolithin A (UA), a gut microbiota-derived metabolite, exhibits potent antioxidant and anti-glycation properties and has demonstrated protective effects in diabetic models. This study aimed to investigate the renoprotective effects of UA in DKD and to determine whether these effects are mediated through inhibition of ferroptosis via activation of the Nrf2/HO-1 signaling pathway. A DKD model was established using db/db mice, which were randomly assigned to four groups: db/m , db/m + UA, db/db , and db/db + UA. After 10 weeks of UA administration by gavage, renal function, histopathological changes, and markers of oxidative stress and ferroptosis were evaluated. In vitro, HK-2 cells were exposed to high glucose to mimic the diabetic milieu, followed by UA treatment to assess cellular injury and associated molecular alterations. The involvement of the Nrf2 pathway was further validated by siRNA-mediated knockdown of Nrf2. UA significantly improved renal function in db/db mice, as indicated by decreased blood urea nitrogen and urinary albumin-to-creatinine ratio (UACR), along with marked attenuation of renal histopathological damage. UA effectively suppressed oxidative stress both in vivo and in vitro, as evidenced by reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), and increased glutathione (GSH) content. Furthermore, UA modulated ferroptosis-related proteins by downregulating ACSL4 and upregulating GPX4 and SLC7A11. These effects were accompanied by enhanced nuclear translocation of Nrf2 and increased expression of HO-1. Notably, Nrf2 knockdown largely abrogated the protective effects of UA. UA attenuates the progression of DKD by activating the Nrf2/HO-1 signaling pathway, thereby inhibiting oxidative stress and ferroptosis. These findings suggest that UA may serve as a promising therapeutic candidate for the treatment of DKD.

Cell Biology and Toxicology
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (CN)
Natural Science Foundation of Hubei Province
Good health and well-being
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon